In advance of a COVID-19 vaccine being available, a group of independent medical advisers to the Centers for Disease Control and Prevention weighed Friday who should get the vaccine first and how.
The federal government plans to distribute 300,000 doses of the drug at no cost, but that doesn't mean treatment will be free. Intravenous infusion charges can run more than $1,000.
The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on hospitalized COVID-19 patients. Researchers concluded the antibody treatment was "unlikely to help."
Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.
A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.
The U.S. Food and Drug Administration has approved the first drug to treat COVID-19. Remdesivir is an antiviral medicine given through an IV for patients needing hospitalization.
Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.
More hospitalized patients are surviving than early in the pandemic. Improved treatments make a big difference, but so does flattening the curve to keep hospitals from overfilling, researchers say.
The average wait time for results has dropped to about three days, but that is still too slow to keep infected people from unknowingly spreading the virus, researchers report.
This week’s Medical Minute, discusses antibodies that play a role in the advancement of Myasthenia Gravis, a condition that affects points of communication between nerves and muscles.
Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.
A vaccine will only work if a lot of people can get immunized. State health officials are working furiously to design outreach and distribution plans, with little clarity from the federal government.
Here's irony: tobacco plants may be key in preventing COVID-19. Two companies are using the plants to produce proteins for a vaccine. One candidate vaccine is already in a clinical trial.
Pediatricians have been asking policy makers to include children in COVID-19 vaccine trials. Now, the FDA has given Pfizer approval to enroll adolescents as young as 12 years old.
